Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement
Source : https://www.hindawi.com/journals/crp/2022/7537510/
Background . We sought to characterize the level of LDL-C control and identify opportunities for improvement and characteristics of patients who were undertreated. Methods . Study patients were from a...
Conclusions: There were important variations in LDL-C control between patients in our health system with the same indication for treatment. Variation in treatment among physicians is an area ripe for quality improvement interventions. This study may be easily reproduced by other medical centers and used for highlighting both patient and...
Share
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35543701/
2022 May 11;101161CIRCGEN121003503. doi: 10.1161/CIRCGEN.121.003503. Online ahead of print. 1 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (W.A.M.). 2...
Conclusions: This study comprises the largest discovery exome-wide and genome-wide association studies for atorvastatin- or rosuvastatin-mediated SAMS to date. Conclusion/Relevance: These novel genetic findings may provide biological/mechanistic insight into this drug-induced toxicity, and help identify at-risk patients before selection of...
Share
Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072011/
We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. 14 trials ( n...
Conclusion: Addition of PCSK9 inhibitors to standard therapy resulted in definite improvement in blood lipid levels compared with therapies that did not include them.
Share
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35508456/
Patients with acute coronary syndrome (ACS) have a high risk of subsequent adverse cardiovascular outcomes, particularly within the first 30 days. Although it is well documented that initiation of statin...
Conclusion: The Lipid Association of India recommends individualized aggressive LDL-C goals after ACS, which can be rapidly achieved with high intensity statin therapy and subsequent goal-directed adjunctive treatment with ezetimibe and PCSK9 inhibitors. Improved treatment of hypercholesterolemia achieved within weeks after ACS has the...
Share
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Source : https://heart.bmj.com/content/early/2022/05/03/heartjnl-2021-320556
Objective To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy. Methods This systematic review included randomised controlled trials that compared PCSK9 inhibitors...
Conclusions: PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular pain.
Share